Valeant Pharmaceuticals Intl (VRX) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their hold rating on shares of Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a report published on Wednesday. HC Wainwright currently has a $20.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts also recently weighed in on the stock. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the company a buy rating in a research report on Wednesday, February 28th. Mizuho upgraded shares of Valeant Pharmaceuticals Intl from an underperform rating to a neutral rating and raised their target price for the stock from $10.00 to $15.00 in a report on Friday, April 6th. Barclays upgraded shares of Valeant Pharmaceuticals Intl from an equal weight rating to an overweight rating and raised their target price for the stock from $20.00 to $34.00 in a report on Wednesday, June 6th. Zacks Investment Research upgraded shares of Valeant Pharmaceuticals Intl from a sell rating to a hold rating in a report on Monday, April 2nd. Finally, Deutsche Bank set a $20.00 target price on shares of Valeant Pharmaceuticals Intl and gave the stock a buy rating in a report on Wednesday, March 21st. Five research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $20.54.

Shares of NYSE:VRX opened at $24.27 on Wednesday. The company has a market capitalization of $8.63 billion, a P/E ratio of 6.34, a PEG ratio of 0.37 and a beta of -0.34. The company has a debt-to-equity ratio of 5.59, a quick ratio of 0.92 and a current ratio of 1.18. Valeant Pharmaceuticals Intl has a fifty-two week low of $10.94 and a fifty-two week high of $27.79.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.29. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.95 billion. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. Valeant Pharmaceuticals Intl’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same period last year, the company posted $1.79 EPS. analysts forecast that Valeant Pharmaceuticals Intl will post 3.33 EPS for the current fiscal year.

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 15,000 shares of the stock in a transaction dated Tuesday, May 15th. The shares were bought at an average cost of $21.83 per share, for a total transaction of $327,450.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.87% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rational Advisors LLC bought a new position in shares of Valeant Pharmaceuticals Intl in the first quarter valued at $1,312,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp grew its stake in shares of Valeant Pharmaceuticals Intl by 1,533.2% in the first quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 501,400 shares of the specialty pharmaceutical company’s stock valued at $10,284,000 after buying an additional 470,700 shares in the last quarter. Tuttle Tactical Management bought a new position in shares of Valeant Pharmaceuticals Intl in the first quarter valued at $1,312,000. Alpine Global Management LLC grew its stake in shares of Valeant Pharmaceuticals Intl by 24.6% in the first quarter. Alpine Global Management LLC now owns 41,750 shares of the specialty pharmaceutical company’s stock valued at $665,000 after buying an additional 8,250 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Valeant Pharmaceuticals Intl by 16.9% in the first quarter. Millennium Management LLC now owns 496,313 shares of the specialty pharmaceutical company’s stock valued at $7,901,000 after buying an additional 71,900 shares in the last quarter. Institutional investors own 46.95% of the company’s stock.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply